Media release detail page

Spexis announces business update call to be held on July 28th

Spexis AG / Key word(s): Conference
Spexis announces business update call to be held on July 28th
25.07.2022 / 19:25

Allschwil, Switzerland, July 20, 2022

Spexis announces business update call to be held on July 28th


  • Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET

Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET.


To participate, please use the following numbers:


France:  +33 (0)1 70 730 3 39

Germany:  +49 (0)69 22222 5197

Italy:   +39 0200638217

Switzerland:  +41 (0)44 580 7279

United Kingdom +44 (0)330 165 4012

United States  +1 646-828-8075


Please dial in approximately 10 minutes prior to the start of the call.  When asked, please provide the name of the event – “Spexis AG - Business and Strategy Update” – and the following confirmation code: 1507661.


The presentation will also be available via webcast:


A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.



For further information, please contact:


For Investors: 
Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
Raimund Gabriel
MC Services
Ph: +49 89 210 228 0
For Media:
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
Dr. Brigitte Keller/Laurie Doyle
MC Services
Europe: +49 89 210 228 0
U.S.: +1 339 832 0752



About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit:

This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.



End of Media Release

show this